Mwyngil Therapeutics bets on weight loss without GLP-1 drugs
Biotech startup Mwyngil Therapeutics (pronounced "mwin-gull") is developing an obesity drug that does not target the GLP-1 receptor, setting it apart from most rivals in the booming weight-loss market. CEO Luba Greenwood, a biotech veteran, said she was not interested in another "me too" GLP-1 candidate. The company enters a field dominated by blockbusters like Ozempic and Wegovy.
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!